Moreover, kaempferol sensitizing pancreatic cancer to Erlotinib treatment may probably be related to the PI3K/AKT signaling pathway and Epidermal growth factor receptor (EGFR), a transmembrane protein involved in TKI resistance. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.